Laborie Medical Technologies
VC Fund
Mississauga, Canada
Laborie Medical Technologies is a global developer, manufacturer and marketer of innovative medical technology and consumables used for the diagnosis and treatment of Urinary and Fecal Incontinence, as well as other pelvic floor disorders in the Urology, Gynecology, and Colorectal fields. Laborie is owned by Audax Group Private Equity based inBoston, MA.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Laborie Medical Technologies invests in
Stages Laborie Medical Technologies invests in
Countries Laborie Medical Technologies invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 8 contacts → | |||
Round size
- Series A
- $26M–$32M
- Venture - Series Unknown
- $11M–$16M
Investment Focus
Industry
- Health Care 5 (63%)
- Medical 4 (50%)
- Medical Device 4 (50%)
- Fitness 1 (13%)
- Therapeutics 1 (13%)
Stage
- Series A 2 (25%)
- Venture - Series Unknown 2 (25%)
- Funding Round 1 (13%)
- Corporate Round 1 (13%)
Country
- United States 4 (50%)
- Israel 2 (25%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Bo Jesper Hansen
Chairman of the Board
|
Chairman of the Board | Total investments: 0 | Find email | |
Gail Ciccione
Chief Operating Officer
|
Chief Operating Officer | Total investments: 0 | Find email | |
Ray Laborie
Founder
|
Founder | Total investments: 0 | Find email | |
Daniel Merz
Chief Technology Officer
|
Chief Technology Officer | Total investments: 0 | Find email | |
Nikki Bruce
Vice President and General Manager
|
Vice President and General Manager | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Bright Uro is an early-stage medical technology company. It is building the next generation of diagnostic devices for Urology. Utilizing advanced hardware, software, and data science can unlock new data streams and offer actionable insight for clinicians. | $32M / Series A / Oct 31, 2024 | ||
| Currently, after surgical removal of tumors found in the bladder, a drug is instilled into the bladder via a catheter. This treatment method is inefficient and ineffective: Urinary bladder cancer has the highest recurrence rates among all types of cancer (70%).Using Vensica’s device, the drug will be instilled in a quick, pain-free proceduresubsequent to the delivery of ultrasound to the urinary bladder. Ultrasound improves the uptake of the drug and its penetration into the bladder wall and is expected to improve the treatment and reduce recurrence rates. | $11M / Venture - Series Unknown / Oct 28, 2024 | ||
| Novocuff is a medical device firm that aims to improve pregnancy outcomes and reduce preterm deliveries caused by PPROM and cervical shortening. | $26M / Series A / Jul 17, 2024 | ||
| I-O Urology provides a patient monitoring system for urology. | $16M / Venture - Series Unknown / Jan 02, 2024 | ||
| Bright Uro is an early-stage medical technology company. It is building the next generation of diagnostic devices for Urology. Utilizing advanced hardware, software, and data science can unlock new data streams and offer actionable insight for clinicians. | $31M / Series A / Nov 30, 2023 | ||
|
GIE Medical
|
GIE Medical is a medical organization that specializes in fitness care, scientific device, fitness diagnostics. | $5M / Corporate Round / Sep 06, 2023 | |
| Currently, after surgical removal of tumors found in the bladder, a drug is instilled into the bladder via a catheter. This treatment method is inefficient and ineffective: Urinary bladder cancer has the highest recurrence rates among all types of cancer (70%).Using Vensica’s device, the drug will be instilled in a quick, pain-free proceduresubsequent to the delivery of ultrasound to the urinary bladder. Ultrasound improves the uptake of the drug and its penetration into the bladder wall and is expected to improve the treatment and reduce recurrence rates. | $16M / Venture - Series Unknown / Nov 01, 2021 | ||
| iTind is an Israeli medical device company. Our company is dedicated to improving men’s healthcare and quality of life via effective, non-surgical solutions for Benign Prostatic Hyperplasia (BPH). The flagship iTind treatment for BPH currently has the EU CE Mark and is approved for sale in the European Union, UK, Israel, Australia, Brazil, and FDAcleared for use in the USA. | Jul 07, 2016 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Laborie Medical Technologies invest in?
Laborie Medical Technologies invests primarily in Health Care, Medical and Medical Device startups, most often at Series A and Venture - Series Unknown stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Laborie Medical Technologies's check size?
Laborie Medical Technologies typically joins rounds of $26M–$32M at Series A and $11M–$16M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Laborie Medical Technologies participates in.
How do I contact Laborie Medical Technologies?
Public channels for Laborie Medical Technologies include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Laborie Medical Technologies?
The team at Laborie Medical Technologies includes Bo Jesper Hansen (Chairman of the Board), Gail Ciccione (Chief Operating Officer) and Ray Laborie (Founder), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
